Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) FCF Margin (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed FCF Margin for 16 consecutive years, with 76.2% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 16124.0% to 76.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18.24% through Dec 2025, down 3873.0% year-over-year, with the annual reading at 18.24% for FY2025, 3873.0% down from the prior year.
  • FCF Margin hit 76.2% in Q4 2025 for Ligand Pharmaceuticals, up from 11.71% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 237.43% in Q4 2024 to a low of 73.26% in Q3 2024.
  • Historically, FCF Margin has averaged 41.69% across 5 years, with a median of 30.62% in 2024.
  • Biggest five-year swings in FCF Margin: skyrocketed 20728bps in 2024 and later plummeted -16124bps in 2025.
  • Year by year, FCF Margin stood at 34.46% in 2021, then soared by 196bps to 101.9% in 2022, then tumbled by -70bps to 30.16% in 2023, then soared by 687bps to 237.43% in 2024, then tumbled by -68bps to 76.2% in 2025.
  • Business Quant data shows FCF Margin for LGNDZ at 76.2% in Q4 2025, 11.71% in Q3 2025, and 32.72% in Q2 2025.